NVNO Stock Overview
A clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
enVVeno Medical Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$3.41 |
52 Week High | US$6.97 |
52 Week Low | US$3.01 |
Beta | 1.22 |
11 Month Change | 2.71% |
3 Month Change | -38.22% |
1 Year Change | -10.26% |
33 Year Change | -52.64% |
5 Year Change | -72.46% |
Change since IPO | -97.40% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation
Jun 26Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Mar 07Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?
Aug 14Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?
Apr 22We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Dec 21enVVeno Medical: Unique Exposure To Venous Treatment Domain
Sep 23We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely
Aug 23enVVeno Medical reports Q2 results
Aug 03We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth
May 10We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Jan 25Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Sep 08Hancock Jaffe Laboratories finance chief sheds interim tag
Dec 31Hancock Jaffe approves 1:25 reverse stock split
Nov 27Shareholder Returns
NVNO | US Medical Equipment | US Market | |
---|---|---|---|
7D | 4.0% | 1.5% | 2.2% |
1Y | -10.3% | 20.8% | 31.6% |
Return vs Industry: NVNO underperformed the US Medical Equipment industry which returned 20.9% over the past year.
Return vs Market: NVNO underperformed the US Market which returned 31.7% over the past year.
Price Volatility
NVNO volatility | |
---|---|
NVNO Average Weekly Movement | 10.4% |
Medical Equipment Industry Average Movement | 8.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVNO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVNO's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 31 | Robert Berman | www.envveno.com |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
enVVeno Medical Corporation Fundamentals Summary
NVNO fundamental statistics | |
---|---|
Market cap | US$59.80m |
Earnings (TTM) | -US$21.24m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs NVNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVNO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$21.24m |
Earnings | -US$21.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.21 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NVNO perform over the long term?
See historical performance and comparison